ClinicalTrials.gg
TerminatedNCT04398667Updated Dec 1, 2023

European Non-interventional Study on Refractory Epilepsy With Developmental Delay

An observational study in Refractory Epilepsy and Development Delay, sponsored by Zogenix, Inc.. Terminated at 19 sites in 4 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2023-12-01.

Sponsored by Zogenix, Inc. (part of UCB S.A.) · Observational

How we know

Why this study was terminated
The clinical research organization went out of business.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
93
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Drug Resistant Epilepsy with a site in Germany — 2 open to participants now, 4 under way, 1 of them phase 3. Drug Resistant Epilepsy · Germany.

Started
2019
with 2 others
Observational
3 of 11
1 open now
Registered
6th of 11
by date
Lead sponsor
1 of 11
Zogenix, Inc.

Among the 11 studies in Drug Resistant Epilepsy with a site in Germany, this one is one of 3 that started in 2019, is one of 3 observational ones, and was the 6th registered.

Drug Resistant Epilepsy

258 studies on the registry are indexed under Drug Resistant Epilepsy; 109 are open to participants now.

Browse Drug Resistant Epilepsy studies →

Open to participants now

2 of the 11 studies in Drug Resistant Epilepsy with a site in Germany are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 68 Drug Resistant Epilepsy studies recruiting now, 27 (40%) set no upper age limit and 40 (59%) stop at 75 or younger; 27 take children under 18; 6 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Drug Resistant Epilepsy with a site in Germany, or all of them as a file.
02

Study summary

This is a multinational, multicentre, non-interventional, retrospective data collection (manual Medical Chart Review).

Read the detailed description

This is a multinational, multicentre, non-interventional, retrospective data collection (manual Medical Chart Review). The identified local site staff (or trained independent data abstractors, if requested by the site) will review the medical records of all participants meeting the eligibility criteria, who have provided a signed inform consent form (ICF) for data collection and analysis. For participants who are less than 18 years of age, in addition to the assent form being signed by the participant, an informed consent would be obtained from parental or legally authorized representative.

In line with the retrospective nature of the study: there is no assignment of a participant to a particular therapeutic strategy; no additional diagnostic or monitoring procedures shall be applied to the participants; epidemiological methods shall be used for the analysis of collected data; the prescription of any medication for the treatment of the epileptic syndrome occur before the collection of the data in this study and is clearly separated from the decision to include the participant in the study.

03

Conditions studied

  • Refractory Epilepsy
  • Development Delay

Keywords

  • Observational
  • Retrospective
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with rare epilepsy syndromes up to the date of the most recent visit at the study site.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥2 years
  • Disease history of at least 24 months from date of first seizure
  • Medical history of epilepsy associated with moderate to severe intellectual disability, cognitive developmental delay or cognitive regression
  • Medical history of onset of seizures in early childhood (≤ 8 years)
  • Failure of adequate trials of two tolerated and appropriately chosen and used Anti-Epileptic Drug (AED) schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom
  • Ongoing epilepsy
  • MRI and EEG data are available for the participant
  • Participants (or their parents/ legal representative as appropriate) have provided written / assent form to collect the data specified.

Exclusion criteria

Exclusion Criteria:

  • Normal cognitive development.
  • Any acute symptomatic seizures in participants with underlying developmental delay.
  • Any progressive intellectual and neurological deterioration conditions.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
93 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Proportion of Participants With and Without Diagnosis of an Epilepsy Syndrome

    Understand the proportion of participants with and without diagnosis of an epilepsy syndrome, as described by the International League Against Epilepsy (ILAE) diagnostic manual located at https://www.epilepsydiagnosis.org/

    Time frame: 5 months

  2. Understand the Clinical Practice Criteria

    Understand the clinical practice criteria used for specific syndromic diagnosis of participants with refractory epilepsy associated with developmental delay.

    Time frame: 5 months

  3. Clinical Practice Diagnostic Criteria Compared to ILAE

    Compare clinical practice diagnostic criteria to those proposed by the ILAE and identify potential areas of educational need.

    Time frame: 5 months

  4. Understand the Time to Formal Diagnosis

    Understand the time to diagnosis, from first seizure to formal diagnosis of a specific syndrome.

    Time frame: 5 months

  5. Unclassified Epilepsy

    Evaluate if unclassified epilepsy can be grouped with common electroclinical phenotype features.

    Time frame: 5 months

07

Study locations

19 sites
  • Unité de neuropédiatrie, CHU Angers
    Angers, France
  • Department of Neurology - Foundation John Bost
    La Force, France
  • Hospital St Louis DRCI, CHU Bicêtre
    Paris, France
  • Charité - Universitätsmedizin Berlin
    Berlin, Germany
  • Institut der Diagnostik der Epilepsien
    Berlin, Germany
  • Zentrum für Sozialpädiatrie und Neuropädiatrie (DBZ), Vivantes Klinikum
    Berlin, Germany
  • Gesellschaft für Epilepsieforschung e. V.
    Bielefeld, Germany
  • Klinik für Epileptologie, Universitätsklinikum Bonn
    Bonn, Germany
  • Klinik Für Kinder- und Jugendmedizin, Neuropadiatrie und Epilepsiezentrum
    Frankfurt, Germany
  • Department of Neurology / Epileptology, University Medicine Greifswald
    Greifswald, Germany
  • Klinik für Kinder-und Jugendmedizin II, Universitätsklinikum Schleswig-Holstein
    Kiel, Germany
  • Epilepsiezentrum Kork
    Kork, Germany
  • Klinik für Neurologie, Heilig Geist-Krankenhaus GmbH
    Köln, Germany
  • Department of Neurologie University of Magdeburg
    Magdeburg, Germany
  • Abteilung für Epileptologie, ZfP Südwürttemberg
    Ravensburg, Germany
  • I.R.C.C.S. Giannina Gaslini
    Genova, Italy
  • Oasi Research Institute
    Troina, Italy
  • Hospital Vall d'Hebron
    Barcelona, Spain
  • Hospital Ruber Internacional
    Madrid, Spain
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2019 to primary completion in Sep 2020, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2020
First posted
May 21, 2020
StartActual
Mar 14, 2019
Primary completionActual
Sep 4, 2020
CompletionActual
Sep 4, 2020
Last update
Dec 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04398667
Lead sponsor
Zogenix, Inc.
Responsible party
Sponsor
First posted
May 21, 2020
Start date
Mar 14, 2019
Primary completion
Sep 4, 2020
Completion
Sep 4, 2020
Last update
Dec 1, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion